Study:
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy +/- Cetuximab in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer (Cetuximab Closed as of 05/14/10)
Rationale:
Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different
ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Monoclonal
antibodies, such as panitumumab, can block tumor growth in different ways. Some block the
ability of tumor cells to grow and spread. Others find tumor cells and help kill them or
carry tumor-killing substances to them. Giving these treatments before surgery may make the
tumor smaller and reduce the amount of normal tissue that needs to be removed. It is not yet
known whether chemotherapy and radiation therapy are more effective when given with or
without panitumumab in treating patients with non-small cell lung cancer. (cetuximab closed
as of 05/14/10)
Purpose:
This randomized phase II trial is studying chemotherapy and radiation therapy to
see how well they work when given with or without panitumumab in treating patients with
stage IIIA non-small cell lung cancer. (cetuximab closed as of 05/14/10)
Study Status: Recruiting
Recruiting:
Clinical Trials Office - Cleveland Clinic Taussig Cancer Cente 866-223-8100
| Condition |
Intervention |
Phase |
|
Lung Cancer |
Biological: panitumumab
Drug: carboplatin
Drug: paclitaxel |
Phase 2 |
Verified by
Radiation Therapy Oncology Group
September, 2012
Sponsored by: Radiation Therapy Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00979212
Study Type: Interventional
Study Design: Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Martin J. Edelman, MD., Study Chair